The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 11-16

  Satake, Hirofumi ^a   Tamura, Kenji ^a   Furihata, Mutsuo ^a   Anchi, Takashi ^a   Sakoda, Hatsune ^a   Kawada, Chiaki ^a   Iiyama, Tatsuo ^a   Ashida, Shingo ^a   Shuin, Taro ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

cDNA microarray; Interferon stimulated gene 15; Prostate cancer

Indexed keywords

SMALL INTERFERING RNA; TUMOR MARKER; UBIQUITIN LIKE MOLECULE INTERFERON STIMULATED GENE 15; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN; UBIQUITINS;

EID: 76049088558     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000600     Document Type: Article

References (20)

1. Gronberg H: Prostate cancer epidemiology. Lancet 361: 859-864, 2003.
2. Hsing AW and Devesa SS: Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3-13, 2001.
3. Feldman BJ and Feldman D: The development of androgenin-dependent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
4. Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261, 2006.
5. Han M, Partin AW, Piantadosi S, Epstein JI and Walsh PC: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166: 416-419, 2001.
6. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
7. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
8. Haas AL, Ahrens P, Bright PM and Ankel H: Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 262: 11315-11323, 1987.
9. Farrell PJ, Broeze RJ and Lengyel P: Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature 279: 523-525, 1979.
10. Korant BD, Blomstrom DC, Jonak GJ and Knight EJ: Interferon-induced proteins. Purification and characterization of a 15,000-dalton protein from human and bovine cells induced by interferon. J Biol Chem 259: 14835-14839, 1984.
11. Loeb KR and Haas AL: The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267: 7806-7813, 1992.
12. Hochstrasser M: Evolution and function of ubiquitin-like protein-conjugation systems. Nat Cell Biol 2: E153-E157, 2000.
13. Uemura M, Tamura K, Chung S, et al: Movel 5α steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99: 81-86, 2008.
14. Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998.
15. de Veer MJ, Holko M, Frevel M, et al: Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69: 912-920, 2001.
16. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC and Zhang DE: High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278: 16608-16613, 2003.
17. Giannakopoulos NV, Luo JK, Papov V, et al: Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 336: 496-506, 2005.
18. Zhao C, Denison C, Huibregtse JM, Gygi S and Kruq RM: Human ISG15 conjugation targets both IFNinduced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA 102: 10200-10205, 2005.
19. Desai SD, Haas AL, Wood LM, et al: Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 66: 921-928, 2006.
20. Kiessling A, Hogrefe C, Erb S, Bobach S, Fuessel S, Wessjohann L and Seliger B: Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 28: 2606-2620, 2009.